EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Current status of carboplatin desensitization therapy for gynecologic malignancies

Hiroshi Nishio iD, Koji Matsumoto iD, Hiroaki Komatsu iD, Mitsunori Morita iD, Takayuki Nagasawa iD, Jiro Suzuki iD, Shin Nishio iD, Mitsuya Ishikawa iD, Toyomi Satoh iD

Journal of Gynecologic Oncology · 2026

DOI: 10.3802/jgo.2026.37.e11 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Gynecologic Oncology, 2026. Verfasst von Hiroshi Nishio und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan. nishio.z3@keio.jp. Hauptthemen laut MEDLINE: Carboplatin, Genital Neoplasms, Female, Desensitization, Immunologic, Drug Hypersensitivity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Platinum-based chemotherapies are widely used in the treatment of gynecologic malignancies and are standard treatment for initial treatment and recurrent diseases. Due to the widespread use of platinum-based regimens, the management of platinum hypersensitivity reactions (HSRs) is an important issue for physicians treating gynecologic malignancies. Patients receiving multiple lines of platinum therapy, with long intervals between platinum lines and history of allergic reaction, and status of germline BRCA mutation are at an increased risk of platinum HSRs. The development of desensitization protocols to allow patients with platinum hypersensitivity to receive further therapy is mandatory. Each institution should work with its' multidisciplinary team to select a protocol that best suits individual practice setting and patient population to maximize patients care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarboplatinGenital Neoplasms, FemaleDesensitization, ImmunologicDrug HypersensitivityAntineoplastic AgentsHumansFemale

Stichwörter der Autor:innen

CarboplatinDrug HypersensitivityHypersensitivity

Substanzen

CarboplatinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan. nishio.z3@keio.jp.
  • Department of Medical Oncology, Hyogo Cancer Center, Akashi, Japan.
  • Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan.
  • Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Japan.
  • Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan.

ORCID-Profile: Hiroshi Nishio, Koji Matsumoto, Hiroaki Komatsu, Mitsunori Morita, Takayuki Nagasawa, Jiro Suzuki, Shin Nishio, Mitsuya Ishikawa, Toyomi Satoh

Zitieren

APA

Nishio, H., Matsumoto, K., Komatsu, H., Morita, M., Nagasawa, T., Suzuki, J., Nishio, S., Ishikawa, M., & Satoh, T. (2026). Current status of carboplatin desensitization therapy for gynecologic malignancies. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2026.37.e11

Vancouver

Nishio H, Matsumoto K, Komatsu H, Morita M, Nagasawa T, Suzuki J, et al. Current status of carboplatin desensitization therapy for gynecologic malignancies. Journal of Gynecologic Oncology. 2026. doi:10.3802/jgo.2026.37.e11

BibTeX
@article{Nishio2026,
  author = {Nishio, Hiroshi and Matsumoto, Koji and Komatsu, Hiroaki and Morita, Mitsunori and Nagasawa, Takayuki and Suzuki, Jiro and Nishio, Shin and Ishikawa, Mitsuya and Satoh, Toyomi},
  title = {Current status of carboplatin desensitization therapy for gynecologic malignancies},
  journal = {Journal of Gynecologic Oncology},
  year = {2026},
  doi = {10.3802/jgo.2026.37.e11}
}
Kostenlos starten →